The Technical Analyst
Vaccitech plc [VACC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Vaccitech plc Price, Forecast, Insider, Ratings, Fundamentals & Signals
11.36% $5.00
America/New_York / 6 nov 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 192.73 mill |
| EPS: | -1.450 |
| P/E: | -3.45 |
| Earnings Date: | Nov 12, 2023 |
| SharesOutstanding: | 38.55 mill |
| Avg Daily Volume: | 0.732 mill |
| RATING 2023-12-01 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -3.45 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.59x |
| Company: PE -3.45 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 2.59 - 3.71 ( +/- 17.75%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-02 | Pelletier Nadege | Buy | 105 000 | Share Option (Right to Buy) |
| 2024-01-02 | Griffiths Graham | Buy | 96 500 | Share Option (Right to Buy) |
| 2024-01-02 | Enright William | Buy | 443 981 | Share Option (Right to Buy) |
| 2024-01-02 | Brown Gemma | Buy | 193 000 | Share Option (Right to Buy) |
| 2023-06-26 | Scheeren Joseph | Buy | 10 000 | Ordinary Shares |
| INSIDER POWER |
|---|
| 40.88 |
| Last 95 transactions |
| Buy: 18 963 250 | Sell: 20 685 755 |
Forecast:
01:40 - $3.56
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $5.00 (11.36% ) |
| Volume | 0.163 mill |
| Avg. Vol. | 0.732 mill |
| % of Avg. Vol | 22.28 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VACC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
VACC
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
Latest Press Releases
2023-11-06 09:05:00 - Press Release
Vaccitech Renames As Barinthus Biotherapeutics To Highlight Strategic Evolution Into A T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, And Cancer
Oxford, united kingdom, nov. 06, 2023 (globe newswire) -- barinthus biotherapeutics plc (nasdaq: brns), formerly vaccitech plc (nasdaq: vacc), a clinical-stage biopharmaceutical company developing novel t cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer will present data from its phase 2 hepatitis b trials of vtp-300 at the american association for the study of liver diseases (aasld) – the liver meeting® 2023, november 10-14 in boston, ma.
2023-09-13 08:00:00 - Press Release
Vaccitech To Host Kol Webinar On Seeking A Functional Cure For Chronic Hepatitis B On September 20, 2023
Oxford, united kingdom, sept. 13, 2023 (globe newswire) -- vaccitech plc (nasdaq: vacc), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel t cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced it will host a key opinion leader (kol) webinar to discuss the current treatment landscape for people living with chronic hepatitis b virus (hbv) infection and potential paths to a functional cure. details are as follows:
2023-08-10 08:00:00 - Press Release
Vaccitech Reports Second Quarter 2023 Financial Results And Recent Corporate Developments
Oxford, united kingdom, aug. 10, 2023 (globe newswire) -- vaccitech plc (nasdaq: vacc), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel t cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the company's progress.
2023-06-21 09:03:00 - Press Release
Vaccitech To Present Positive Final Data At Easl Congress For Phase 1b/2 Hbv002 Study In Adults With Chronic Hepatitis B
Oxford, united kingdom, june 21, 2023 (globe newswire) -- vaccitech plc (nasdaq: vacc), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics for the treatment of autoimmunity, chronic infectious diseases and cancer, will present positive final data from the hbv002 clinical trial at the european association for the study of the liver (easl) congress 2023 – the international liver congresstm taking place june 21-24 in vienna, austria. hbv002 (nct04778904) is a phase 1b/2a clinical trial of vtp-300 in adults with chronic hepatitis b (chb). the data will be presented as a poster at easl on saturday, june 24 (poster id: sat-198), by eleanor barnes, professor of hepatology and experimental medicine at oxford university.
2022-10-03 16:30:00 - Press Release
Vaccitech To Present At Upcoming October Investor & Scientific Conferences
Oxford, united kingdom, oct. 03, 2022 (globe newswire) -- vaccitech plc (nasdaq: vacc), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the company's chief scientific officer, dr. thomas g. evans, vice president, corporate development, nick fullenkamp, senior vice president, synthetic immunotherapies, dr. geoffrey lynn, and senior research development scientist, dr. hugh welles will be participating in the following conferences in october.
Latest News
2023-06-21 09:03:00 - GlobeNewsWire
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
OXFORD, United Kingdom, June 21, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics for the treatment of autoimmunity, chronic infectious diseases and cancer, will present positive final data from the HBV002 clinical trial at the European Association for the Study of the Liver (EASL) Congress 2023 – The International Liver CongressTM taking place June 21-24 in Vienna, Austria. HBV002 (NCT04778904) is a Phase 1b/2a clinical trial of VTP-300 in adults with chronic Hepatitis B (CHB). The data will be presented as a poster at EASL on Saturday, June 24 (Poster ID: SAT-198), by Eleanor Barnes, Professor of Hepatology and Experimental Medicine at Oxford University.
2023-04-05 13:40:01 - InvestorPlace
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve's possible response.
2022-10-03 16:30:00 - GlobeNewsWire
Vaccitech to Present at Upcoming October Investor & Scientific Conferences
OXFORD, United Kingdom, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Scientific Officer, Dr. Thomas G. Evans, Vice President, Corporate Development, Nick Fullenkamp, Senior Vice President, Synthetic Immunotherapies, Dr. Geoffrey Lynn, and Senior Research Development Scientist, Dr. Hugh Welles will be participating in the following conferences in October.
2022-09-07 16:01:00 - GlobeNewsWire
Vaccitech to Present at Upcoming September Investors Conferences
OXFORD, United Kingdom, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will be participating in the following investment conferences in September.
2022-09-07 13:33:19 - Zacks Investment Research
Vaccitech PLC Sponsored ADR (VACC) Upgraded to Buy: Here's Why
Vaccitech PLC Sponsored ADR (VACC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2022-06-22 13:48:08 - Benzinga
Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens
Vaccitech plc (NASDAQ: VACC) announced an update to the interim analysis of safety and efficacy data from the HBV002 study evaluating ChAdOx1-HBV and MVA-HBV vaccines (VTP-300) in chronic HBV patients who are virally suppressed with oral anti-viral therapies. In the VTP-.
2022-06-06 16:15:00 - GlobeNewsWire
Vaccitech to Present at the Jefferies Healthcare Conference
OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Jefferies Global Healthcare Conference at 8:30 a.m. EDT on Wednesday, June 8, 2022 in New York City.
2022-05-20 11:30:00 - GlobeNewsWire
Vaccitech to Present at the H.C. Wainwright Global Investment Conference
OXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will present at the H.C. Wainwright Global Investment Conference at 12:00 p.m. EDT on Tuesday, May 24, 2022. The conference will be held both in person in Miami and virtually.
2022-04-03 19:57:11 - Seeking Alpha
Vaccitech: Aiming For A Cure In Chronic Hepatitis B
Vaccitech (NASDAQ: VACC) is known to be the spin-off from Oxford University behind AstraZeneca Sars-Cov-2 vaccine.
2022-03-07 08:00:00 - GlobeNewsWire
Vaccitech to Present at the Barclays Global Healthcare Conference 2022
OXFORD, United Kingdom, March 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Barclays Global Healthcare Conference at 2:05 p.m. EDT on Tuesday, March 15, 2022, in Miami.